LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Akcijų sąrašas・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

27.51 -1.19

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.24

Max

27.6

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-10M -67M
Pelnas, tenkantis vienai akcijai	-1.01
Pelno marža	-7,753.425
Darbuotojai	186
EBITDA	-3.2M -66M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+98.73% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	475M 2B
Ankstesnė atidarymo kaina	28.7
Ankstesnė uždarymo kaina	27.51

Naujienos nuotaikos

By Acuity

50%

158 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

18.91 / 20.63 Palaikymas ir pasipriešinimas

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-14 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

2025-12-13 00:04; UTC

Įsigijimai, susijungimai, perėmimai

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

2025-12-14 23:46; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Some Tailwinds -- Market Talk

2025-12-14 23:36; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2025-12-14 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue to Take Full Control of US$101M Copper Miner Alta

2025-12-14 22:02; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

2025-12-14 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue: Alta Owns the Canariaco Project in Northern Peru

2025-12-14 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

2025-12-14 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue: Agreement Implies Total Equity Value of C$139 Million

2025-12-14 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

2025-12-14 21:59; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue to Acquire Remaining 64% of Alta Copper

2025-12-14 17:00; UTC

Uždarbis

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

2025-12-14 08:30; UTC

Įsigijimai, susijungimai, perėmimai

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

2025-12-13 16:48; UTC

Įsigijimai, susijungimai, perėmimai

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

2025-12-13 08:00; UTC

Įsigijimai, susijungimai, perėmimai

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

2025-12-13 07:00; UTC

Įsigijimai, susijungimai, perėmimai

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

2025-12-13 00:24; UTC

Įsigijimai, susijungimai, perėmimai

Want a Piece Of SpaceX? -- Barrons.com

2025-12-12 23:49; UTC

Įsigijimai, susijungimai, perėmimai

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

2025-12-12 22:52; UTC

Rinkos pokalbiai

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

2025-12-12 22:32; UTC

Uždarbis

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

2025-12-12 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-12 20:45; UTC

Uždarbis

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

2025-12-12 20:41; UTC

Rinkos pokalbiai

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

2025-12-12 20:20; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

2025-12-12 19:23; UTC

Uždarbis

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

2025-12-12 18:35; UTC

Įsigijimai, susijungimai, perėmimai

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

2025-12-12 18:33; UTC

Įsigijimai, susijungimai, perėmimai

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

2025-12-12 18:31; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

2025-12-12 17:49; UTC

Uždarbis

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

2025-12-12 17:34; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

98.73% į viršų

12 mėnesių prognozė

Vidutinis 54.67 USD 98.73%

Aukščiausias 90 USD

Žemiausias 21 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Celldex Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

158 / 374 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.